Welcome to our dedicated page for ANBIO BIOTECHNOLOGY SEC filings (Ticker: NNNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anbio Biotechnology (NNNN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Global Market. Anbio files with the U.S. Securities and Exchange Commission in connection with its initial public offering and ongoing reporting obligations related to its global in vitro diagnostics business.
Investors can review Anbio’s registration statement on Form F-1, which describes its offering of Class A ordinary shares, intended use of proceeds for expanding its sales and distribution network, research and development, and working capital and general corporate purposes. Subsequent current reports on Form 6-K supply updates on significant corporate events. For example, a Form 6-K details the termination of YCM CPA INC. as Anbio’s independent registered public accounting firm and the appointment of HTL International, LLC, along with disclosures that there were no disagreements or reportable events as defined under Regulation S-K.
Through this page, users can monitor Anbio’s periodic and current reports to understand how it presents its IVD platforms, global operations and risk factors in official filings. Stock Titan enhances these documents with AI-powered summaries that explain key sections, helping readers interpret complex accounting, auditing and disclosure language. As new filings are posted to the SEC’s EDGAR system, they are made available here with structured access to exhibits and narrative sections.
In addition to registration and current reports, this page can be used to track future annual reports on Form 20-F, interim updates on Form 6-K and other relevant submissions, offering a centralized view of Anbio’s regulatory reporting history and governance developments.
Anbio Biotechnology shareholders approved significant changes to the company’s capital structure and governance at a Class A meeting and an extraordinary general meeting. As of the April 22, 2026 record date, 43,891,200 Class A shares and 100,000,000 Class B shares were outstanding.
Investors backed a Share Capital Reduction that cuts par value, followed by an Authorised Share Capital Increase to US$3,000 divided into 3,000,000,000,000 shares, adding new Class C ordinary and preference shares. Voting rights on Class B shares will rise from 50 to 500 votes per share, and each Class B share will become convertible into Class A shares under new terms.
Shareholders also authorised the board to implement one or more share consolidations of Class A shares at ratios between 2‑for‑1 and 10,000‑for‑1 within three years. A second amended and restated memorandum and articles of association was adopted, reflecting these changes, raising the threshold to requisition meetings to a majority of voting rights, and adding an exclusive forum and jurisdiction clause.
Anbio Biotechnology is calling a May 15, 2026 Class A meeting and an extraordinary general meeting to overhaul its share capital and governance. Shareholders will vote on reducing par value, then massively increasing authorised capital to up to 800,000,000,000 Class A, 200,000,000,000 Class B, 1,000,000,000,000 Class C and 1,000,000,000,000 preference shares, plus creating non‑voting Class C shares. A key proposal would raise Class B voting power from 50 to 500 votes per share, sharply diluting Class A voting influence. Class B shares would become convertible into Class A, and the board would be authorised to execute one or more reverse share splits of Class A in a 2‑for‑1 to 10,000‑for‑1 range to help support Nasdaq bid‑price compliance. An updated memorandum and articles would embed these changes, tighten meeting requisition thresholds and add an exclusive forum clause. The board unanimously recommends voting in favour of all proposals.
Anbio Biotechnology filed Amendment No. 1 to its Form 20-F for the year ended December 31, 2025. The amendment’s sole purpose is to update the cover page to check that the company is a well-known seasoned issuer as defined in Rule 405 of the Securities Act.
The company states that no other changes have been made to the original annual report and that the amendment does not reflect events after the original filing. As of December 31, 2025, there were 43,891,200 Class A Ordinary Shares and 100,000,000 Class B Ordinary Shares issued and outstanding.
Anbio Biotechnology CFO Song Suki has filed an initial insider ownership report on Form 3 for ticker NNNN. The filing establishes her status as an officer but does not report any insider buy, sell, or other share transactions in this submission.
Anbio Biotechnology director Hartzler Nancy filed a Form 3 insider report. The filing identifies her as a director of Anbio Biotechnology (ticker NNNN) and shows no reported transactions in company securities, with zero buys, zero sells, and no derivative exercises recorded.
Anbio Biotechnology CEO Michael Lau has filed an initial Form 3 as an officer of the company. This filing identifies him as the Chief Executive Officer but, in this excerpt, shows no reportable holdings or insider transactions in Anbio Biotechnology securities at the time of the filing.
Anbio Biotechnology executive Chris Tian, the company’s CBO, filed an initial Form 3 as a reporting person for NNNN. This filing does not list any transactions, holdings, or derivative positions, serving solely as a baseline disclosure of insider status at the company.
Anbio Biotechnology director XU CANY filed an initial ownership report on Form 3 as an insider of the company. The filing does not list any specific share holdings or recent transactions, serving only to formally register this individual’s insider status with the issuer.
Anbio Biotechnology, a Cayman Islands in vitro diagnostics company, files its annual report describing its global holding structure and recent listing on Nasdaq. The company completed an IPO of 1,600,000 Class A Ordinary Shares at $5.00 per share, raising gross proceeds of $8 million.
The capital structure is highly concentrated, with 43,891,200 Class A and 100,000,000 Class B shares outstanding; each Class B share carries 50 votes, giving two shareholders 99.22% of total voting power. Anbio highlights reliance on a small number of suppliers and customers, shifting revenue away from COVID-19 tests toward other IVD products, and significant regulatory, IVDR transition, data integrity and reimbursement risks.
The report also warns about potential volatility in its small public float, complexities of being a foreign private issuer and emerging growth company, and challenges in maintaining internal controls, cybersecurity, intellectual property protection, and experienced management capable of meeting U.S. public company requirements.
Anbio Biotechnology reported a change in its independent registered public accounting firm. On February 11, 2026, the Board of Directors and Audit Committee approved and ratified the appointment of GGF CPA LTD to audit the company’s financial statements, effective the same date. The report states that during the two most recent fiscal years ended December 31, 2025 and 2024, and subsequent interim periods before this engagement, neither the company nor anyone on its behalf consulted GGF CPA LTD. A letter from the former auditor, HTL International, LLC, addressed to the U.S. Securities and Exchange Commission is included as Exhibit 16.1.